Biogen Reports Record Revenues for Both the Full Year and Q4 2018, $13.5 Billion and $3.5 Billion, Respectively
Biogen Reports Record Revenues for Both the Full Year and Q4 2018, $13.5 Billion and $3.5 Billion, Respectively
January 29, 2019
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human
April 24, 2024